866-997-4948(US-Canada Toll Free)

Brain Metastasis - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 111 Pages

Brain Metastasis - Pipeline Review, H1 2014

Summary

Global Markets Directs, Brain Metastasis - Pipeline Review, H1 2014, provides an overview of the Brain Metastasiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Metastasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Brain Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Brain Metastasis Overview 8
Therapeutics Development 9
Pipeline Products for Brain Metastasis - Overview 9
Pipeline Products for Brain Metastasis - Comparative Analysis 10
Brain Metastasis - Therapeutics under Development by Companies 11
Brain Metastasis - Therapeutics under Investigation by Universities/Institutes 13
Brain Metastasis - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Brain Metastasis - Products under Development by Companies 16
Brain Metastasis - Products under Investigation by Universities/Institutes 17
Brain Metastasis - Companies Involved in Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
Sanofi 19
GlaxoSmithKline plc 20
Takeda Pharmaceutical Company Limited 21
Cell Therapeutics, Inc. 22
Nanobiotix 23
Spectrum Pharmaceuticals, Inc. 24
Philogen S.p.A. 25
Nerviano Medical Sciences S.r.l. 26
AngioChem Inc. 27
Diffusion Pharmaceuticals LLC 28
biOasis Technologies Inc. 29
Puma Biotechnology, Inc. 30
AbbVie Inc. 31
Brain Metastasis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
neratinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
paclitaxel poliglumex - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lucanthone hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ANG-1005 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
lapatinib ditosylate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
veliparib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
dabrafenib + trametinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
dabrafenib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cabazitaxel - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
trastuzumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
radretumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Trans Sodium Crocetinate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PB-357 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Therapeutic p53 Gene Agent - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
TAK-285 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BT-2111 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ANG-4043 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NBTX-IV - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NMSE-973 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Brain Metastasis - Recent Pipeline Updates 79
Brain Metastasis - Dormant Projects 99
Brain Metastasis - Discontinued Products 100
Brain Metastasis - Product Development Milestones 101
Featured News & Press Releases 101
Nov 12, 2013: Study Demonstrates biOasis Technologies' Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-Tumor Barrier 10 Times Greater Than Herceptin Alone 101
Oct 08, 2013: Angiochem to Present at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 101
Jun 26, 2013: Nanobiotix Announces Selection Of Its Second NanoXray Product NBTX-IV And Collaboration With National Cancer Institute For Development 102
Apr 09, 2013: biOasis Provides Update On BT2111-Herceptin Program 103
Dec 03, 2012: Geron Discontinues Development Of Brain Cancer Drug Candidate GRN1005 103
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 103
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 104
Jun 27, 2011: to-BBB Starts Clinical Trial In Patients With Brain Metastases 107
Jun 07, 2010: Angiochem Presents Complete Phase I/II Clinical Data Of ANG1005 For Treatment Of Brain Metastases 107
May 27, 2010: YM BioSciences Enrolls First US Patient In Phase II Randomized, Double-Blind Brain Metastases Trial For Nimotuzumab 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 111
Disclaimer 111

List of Table

List of Tables
Number of Products under Development for Brain Metastasis, H1 2014 9
Number of Products under Development for Brain Metastasis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Brain Metastasis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 18
Brain Metastasis - Pipeline by Sanofi, H1 2014 19
Brain Metastasis - Pipeline by GlaxoSmithKline plc, H1 2014 20
Brain Metastasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 21
Brain Metastasis - Pipeline by Cell Therapeutics, Inc., H1 2014 22
Brain Metastasis - Pipeline by Nanobiotix, H1 2014 23
Brain Metastasis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 24
Brain Metastasis - Pipeline by Philogen S.p.A., H1 2014 25
Brain Metastasis - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 26
Brain Metastasis - Pipeline by AngioChem Inc., H1 2014 27
Brain Metastasis - Pipeline by Diffusion Pharmaceuticals LLC, H1 2014 28
Brain Metastasis - Pipeline by biOasis Technologies Inc., H1 2014 29
Brain Metastasis - Pipeline by Puma Biotechnology, Inc., H1 2014 30
Brain Metastasis - Pipeline by AbbVie Inc., H1 2014 31
Assessment by Monotherapy Products, H1 2014 32
Assessment by Combination Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
Brain Metastasis Therapeutics - Recent Pipeline Updates, H1 2014 79
Brain Metastasis - Dormant Projects, H1 2014 99
Brain Metastasis - Discontinued Products, H1 2014 100

List of Chart

List of Figures
Number of Products under Development for Brain Metastasis, H1 2014 9
Number of Products under Development for Brain Metastasis - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 32
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *